Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026

Rhea-AI Summary

Standard BioTools (NASDAQ: LAB) announced it will release its second quarter 2026 financial results on Wednesday, August 5, 2026, after the U.S. market close. The company develops standardized next-generation life science tools for biomedical research, provided for research use only and not for diagnostic procedures.

Market Context

Two prior earnings-date records were negative at -1% and -1.59%. That platform history adds a negati...

Analysis

Two prior earnings-date records were negative at -1% and -1.59%. That platform history adds a negative comparison point to LAB’s scheduled 2Q26 results announcement; the upcoming release remains the key information gap, with low short positioning as a separate risk context.

Key Figures

Results date: August 5, 2026

1 metrics

Results date August 5, 2026 Second quarter 2026 financial results after U.S. market close

Previous Earnings date Reports

2 past events · Latest: Apr 21 (Neutral)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 21	Earnings date	Neutral	-1.0%	First-quarter results scheduled for release after U.S. market close
Feb 10	Earnings date	Neutral	-1.6%	Fourth-quarter and full-year results scheduled for February 24

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Both prior earnings-date announcements were followed by negative 24-hour reactions of -1% and -1.59%, diverging from the neutral scheduling news.

Key Terms

research use only, limited use label license

2 terms

research use only technical

"For Research Use Only."

A "research use only" label means a laboratory product, test, or instrument is intended solely for scientific research and has not been cleared or approved for clinical diagnosis, treatment, or medical decision-making. This matters to investors because it limits how the item can be marketed and sold, restricting the customer base and regulatory pathway—like a vehicle built for racetracks rather than public roads, requiring extra approvals to reach broader commercial markets.

limited use label license regulatory

"Limited Use Label License and other terms may apply"

A limited use label license is a legal permission that lets one party use another party’s product name, logo, packaging copy, or regulatory label in specific, narrowly defined ways—for example for marketing, distribution, or regulatory filings—and usually for a set time, territory, or purpose. It matters to investors because such licenses can enable or restrict a partner’s ability to sell, market, or claim regulatory status for a product, affecting revenue streams, market access, and the value of collaboration deals; think of it like borrowing a branded billboard but only for certain roads and dates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish its second quarter 2026 financial results on Wednesday, August 5, 2026, after U.S. market close.

About Standard BioTools Inc.

Standard BioTools, Inc. (NASDAQ: LAB), is committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world-class management team. The Company's established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster.

For Research Use Only. Not for use in diagnostic procedures.

Limited Use Label License and other terms may apply: standardbio.com/legal/terms-and-conditions/.
Patent and License Information: standardbio.com/legal/notices.

Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2026 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.

Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

Investor Contact:
ir@standardbio.com

FAQ

When will Standard BioTools (NASDAQ: LAB) report its Q2 2026 earnings?

Standard BioTools will publish its Q2 2026 financial results on Wednesday, August 5, 2026, after U.S. market close. According to Standard BioTools, the announcement will follow the end of the regular trading session that day.

At what time of day will Standard BioTools (LAB) release Q2 2026 results?

Standard BioTools plans to release Q2 2026 results after U.S. market close on August 5, 2026. According to Standard BioTools, the timing is specified only as post-close, with no exact hour provided.

What does Standard BioTools (LAB) do in the life science tools industry?

Standard BioTools provides standardized next-generation solutions to help biomedical researchers develop therapeutics faster. According to Standard BioTools, its portfolio focuses on life science tools delivered through strategic consolidation and best-in-class operations for research applications.

Are Standard BioTools products for diagnostic use?

Standard BioTools products are for Research Use Only and not for diagnostic procedures. According to Standard BioTools, its tools are intended to support biomedical research rather than serve as clinical diagnostic devices in patient care.

Where can investors find legal and patent information about Standard BioTools (LAB)?

Investors can review legal terms at standardbio.com/legal/terms-and-conditions and patent and license information at standardbio.com/legal/notices. According to Standard BioTools, trademark details are available at standardbio.com/legal/trademarks for further reference.

How can investors contact Standard BioTools regarding its Q2 2026 results?

Investors can contact Standard BioTools by emailing ir@standardbio.com. According to Standard BioTools, this investor relations contact is provided for questions related to financial results, corporate information, and engagement with the shareholder community.